Content about XML

March 26, 2014

Although observers have been arguing for many years that conflicts of interest in medical research hurt patient care and diminish research integrity, the issue has lately become particularly salient to policy makers, researchers, institutions, and other stakeholders. The result is an environment with increased suspicion about the relationships between industry, research institutions, and physicians and greater regulation of these relationships.

Although observers have been arguing for many years that conflicts of interest in medical research hurt patient care and diminish research integrity, the issue has lately become particularly salient to policy makers, researchers, institutions, and other stakeholders. The result is an environment with increased suspicion about the relationships between industry, research institutions, and physicians and greater regulation of these relationships.

March 26, 2014

Patient requests for access to drugs and biologics prior to their approval has long created a dilemma for biotechnology companies. This document provides "Points to Consider" for biotechnology companies confronting these issues.

Patient requests for access to drugs and biologics prior to their approval has long created a dilemma for biotechnology companies. This document provides "Points to Consider" for biotechnology companies confronting these issues.

Read the document (183 KB PDF)

March 11, 2014

We are the world’s largest biotechnology trade association providing advocacy, business development, and communications services for more than 1,000 members around the world.

We champion biotechnology and advocate for our members – both large and small.

We represent companies at all stages of development, from start-ups to Fortune 500s.

Members focus on:

March 11, 2014

Our members are integral in the development of our advocacy efforts, and this takes shape in the form of staff-level committees. Through these committees, our members have a seat at the table to effectively influence our policy development and public outreach.

Areas of focus include:

December 13, 2013

Position Title: Associate/Deputy General Counsel* for Agriculture & Environment

            (*Exact title will depend on seniority of individual hired for the position)

Department: Legal and Intellectual Property

Reports to: General Counsel & Head of Public Policy    

September 26, 2013

Position Title:            Assistant, Vaccines, Biodefense and Diagnostics Policy

Department:          Policy

August 28, 2013

Got questions? This page might have your answer. 

Q. Is there a cost to speak? 
A. This differs for each event. Generally, speakers in breakout sessions may be given complimentary registrations whereas all company presentations require registrations. There are discounted packages available. 

August 28, 2013

Increased Visibility = Increased Opportunity
Click to find out more

 

Increased Visibility = Increased Opportunity

BIO speakers represent the most thought-provoking, diverse talents from all corners of the industry – healthcare, to industrial and environmental, to finance and business development.

Benefits of speaking at a BIO event, where innovation and education come together, include:

August 21, 2013

YES!  I want to join BIO PAC and help advocate biotechnology.  I understand that my personal contribution is completely voluntary and will be used to support the campaigns of candidates for federal office.

August 21, 2013

YES! I want to support BIO PAC and help advocate biotechnology. BIO PAC financially supports candidates who understand our industry. I understand that my personal contribution is completely voluntary and will be used to support the campaigns of candidates for federal office.

August 9, 2013

Be a Thought Leader at an Upcoming BIO Event

BIO offers a plethora of speaking opportunities throughout the year all over the globe. Share your expertise in front of key decision makers in the biotechnology field. Select your BIO platform based upon your regional or industry expertise:

May 29, 2013

Position Title:       Manager, Event & Health Communications

Department:         Communications

Reports to::           Sr. Director, Health Communications and Director, Events Communications

Position summary: 

December 6, 2012

As an exclusive members-only benefit, BIO offers complimentary One-on-One meeting rooms during the JP Morgan Healthcare Conference, taking place January 7-10, 2013, in San Francisco.

JP Morgan Healthcare Conference

July 19, 2012

The PMDxWorking Group endeavors to foster a positive public policy environment that maximizes the potential impact of the personalized medicine industry for the benefit of patients.

The PMDxWorking Group endeavors to foster a positive public policy environment that maximizes the potential impact of the personalized medicine industry for the benefit of patients. With a focus on improving legislative, intellectual property,regulatory, and reimbursement frameworks, the PMDxWorking Group seeks to better align the incentives connecting the research, development and commercialization of personalized medicine products.

June 27, 2012

Department: Federal Government Relations 

Reports to: Senior Director, Federal Government Relations 

Primary Purpose of the Position:  

This position will help manage BIO’s federal government relations lobbying and research efforts related to biopharmaceutical issues including Medicare/Medicaid reimbursement, the FDA drug approval process, and implementation of health care reform. 

 Responsibilities:

June 20, 2012

Using an input output “I-O” approach to estimating the economic impact of academic licensing, and summing over the 15 years of available data for academic U.S. AUTM Survey respondents, the total contribution of these academic licensors to gross industry output ranges from $199B to $836B, in 2005 $US Dollars; contributions to GDP range from $86B to $388B, in 2005 $US Dollars.

Summary:

June 19, 2012

At a time when the global economy struggles to recover from a severe recession and uncertainty remains regarding future economic growth, bioscience industry development is generating significant attention both globally and at home.

June 19, 2012

This report examines the role played by IPRs in both upstream and downstream phases of the research, development and commercialization of biotechnology products and provides a review and analysis of the existing body of knowledge concerning the role of IPRs.

Executive Summary

1) This report was commissioned by the Biotechnology Industry Organization (BIO).

2) This report examines the role played by IPRs in both upstream and downstream phases of the research, development and commercialization of biotechnology products and inventions in developed, emerging and developing economies.

3) The report provides a review and analysis of the existing body of knowledge concerning the role of IPRs more generally as well as specifically in biopharmaceutical and biotechnological innovation.

May 21, 2012

The International Food Information Council (IFIC) survey, “Consumer Perceptions of Food Technology & Sustainability”, shows U.S. consumers overwhelmingly support current federal rules for labeling foods. 

SUMMARY
The International Food Information Council (IFIC) survey, “Consumer Perceptions of Food Technology & Sustainability”, shows U.S. consumers overwhelmingly support current federal rules for labeling foods. Of the small percentage of consumers who want more detail on their labels, only 3 percent (or 1 percent of the total sample) cited biotechnology as an information need on the label.
 
May 18, 2012

Natural biological processes have been employed for food production for more than 8,000 years. Bread, cheese, yogurt, beer and wine, vinegar, and many other foods are produced through microbial fermentation or enzymatic activity.

Biotechnology’s Impact on Food Ingredients

February 21, 2012

Panelists at the CEO & Investor Conference discuss the state-of-play on valuation for emerging biotech companies

The 14th Annual BIO CEO & Investor Conferenceplenary session – Value Drivers Under the Influence – started on a high note, with Michael Margolis, RPh, Managing Director of Healthcare Investment Banking at ROTH Capital Partnerspointing out that ‘we’re seeing the markets open up right now with lots of pharmaceutical and biotech activity.’

January 25, 2012

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, hosted a media briefing on January 23 to share BIO’s advocacy accomplishments in 2011 and policy priorities for 2012.

January 15, 2012

Industrial & Environmental — Develops biotechnology industry policy on environmental and industrial biotechnology issues, promotes the use of industrial enzymes, conversion of biomass to energy and chemicals, and innovative clean up technologies.

Facts

Description